Cargando…
Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
Tocilizumab is widely being used to treat COVID-19. Although reducing systemic inflammation, it also increases the risk for secondary infections as a result of the immunosuppression produced. We report the case of a 69-year-old patient admitted to the ICU with severe respiratory distress caused by C...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826035/ https://www.ncbi.nlm.nih.gov/pubmed/33520634 http://dx.doi.org/10.1016/j.mmcr.2021.01.002 |